ArticlePharmaceuticals (Basel, Switzerland)2012
DNA methylation as clinically useful biomarkers-light at the end of the tunnel.
Article in Pharmaceuticals (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- A Comprehensive Examination of the Role of Epigenetic Factors in Multiple Sclerosis.International journal of molecular sciences · 2024Review
- HpaII-assisted and linear amplification-enhanced isothermal exponential amplification fluorescent strategy for rapid and sensitive detection of DNA methyltransferase activity.Analytical and bioanalytical chemistry · 2023Article
- Article
- Epigenetics and cell cycle regulation in cystogenesis.Cellular signalling · 2020Review
- Circulating nucleic acids in the plasma and serum as potential biomarkers in neurological disorders.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020Review
- Article
- Molecular Biomarkers for Gestational Diabetes Mellitus.International journal of molecular sciences · 2018Review
- CpG Island Methylation Patterns in Relapsing-Remitting Multiple Sclerosis.Journal of molecular neuroscience : MN · 2018Article
- Identification of differentially methylated BRCA1 and CRISP2 DNA regions as blood surrogate markers for cardiovascular disease.Scientific reports · 2017Article
- DNA methylation-based variation between human populations.Molecular genetics and genomics : MGG · 2017Review
- DifferentialFrontiers in cellular neuroscience · 2017Article
- Diagnostic Value of the Methylation of Multiple Gene Promoters in Serum in Hepatitis B Virus-Related Hepatocellular Carcinoma.Disease markers · 2017Article
- Deciphering the role of DNA methylation in multiple sclerosis: emerging issues.Auto- immunity highlights · 2016Article
- Terahertz molecular resonance of cancer DNA.Scientific reports · 2016Article
- Identifying Significant Features in Cancer Methylation Data Using Gene Pathway Segmentation.Cancer informatics · 2016Article
- DNA methylation: conducting the orchestra from exposure to phenotype?Clinical epigenetics · 2016Review
- Article
- In silico Identification of SFRP1 as a Hypermethylated Gene in Colorectal Cancers.Genomics & informatics · 2014Article
- Review
- Systems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinoma.BMC systems biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A recent expansion of our knowledge about epigenetic changes strongly suggests that epigenetic rather than genetic features better reflect disease development, and consequently, can become more conclusive biomarkers for the detection and diagnosis of different diseases. In this paper we will concentrate on the current advances in DNA methylation studies that demonstrate a direct link between abnormal DNA methylation and a disease. This link can be used to develop diagnostic biomarkers that will precisely identify a particular disease. It also appears that disease-specific DNA methylation patterns undergo unique changes in response to treatment with a particular drug, thus raising the possibility of DNA methylation-based biomarkers for the monitoring of treatment efficacy, for prediction of response to treatment, and for the prognosis of outcome. While biomarkers for oncology are the most obvious applications, other fields of medicine are likely to benefit as well. This potential is demonstrated by DNA methylation-based biomarkers for neurological and psychiatric diseases. A special requirement for a biomarker is the possibility of longitudinal testing. In this regard cell-free circulating DNA from blood is especially interesting because it carries methylation markers specific for a particular disease. Although only a few DNA methylation-based biomarkers have attained clinical relevance, the ongoing efforts to decipher disease-specific methylation patterns are likely to produce additional biomarkers for detection, diagnosis, and monitoring of different diseases in the near future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.